Gilead Sciences: What’s Next in Hepatitis C?
June 23, 2016 at 11:48 AM EDT
What's next for Gilead Sciences ( GILD ) hepatitis C program? Not much, says Leerink's Geoffrey Porges after speaking with Gilead's Chief Scientific Officer Norbert Bischofberger and Chief Financial Officer Robin Washington . He explains why:
